"Magne, N." . "Mickisch, G." . "Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity." . "Bracarda, S." . "Osborne, S." . "Ivanov, S." . "Fernebro, E." . "A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN"@en . "Bellmunt, J." . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "58774" . "S" . "Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity."@en . "A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN"@en . "Gore, M." . . . . "0923-7534" . "RIV/61989592:15110/13:33144214" . . . "RIV/61989592:15110/13:33144214!RIV14-MSM-15110___" . . . . "VEGF; interferon; immunotherapy; bevacizumab; angiogenesis; renal cell carcinoma"@en . "17"^^ . . . "Melichar, Bohuslav" . "Moorselaar, R." . "[7AC871651291]" . . "Staehler, M." . "24" . . . "Matveev, V." . . "Annals of Oncology" . "A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN" . "Jethwa, S." . "10.1093/annonc/mdt228" . "Mulders, P." . "Zyryanov, A." . "Alekseev, B." . . "7"^^ . . "A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN" . "1"^^ . . . "15110" . "9" . "Janciauskiene, R." .